Overview

Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to document the timing of improvement in atopic dermatitis symptoms and severity following the application of crisaborole ointment 2% in patients 2 years or older with mild to moderate atopic dermatitis. Crisaborole ointment 2% will be applied topically twice daily for four weeks and progress will be assessed by photography and patient-reports.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Pfizer